TREM2 Agonism to Rescue APOE4-Induced Microglial Dysfunction

Therapeutic Hypotheses: APOE4 Targeting in Alzheimer's Disease

Hypothesis 1: APOE4 Structural Correction by Small Molecule Correctors

Title: Pharmacological correction of APOE4 misfolding as a disease-modifying strategy

Mechanism: APOE4 adopts a pathological confirmation with aberrant interdomain interaction, promoting aggregation and gain-of-toxic-function. Small molecule correctors (e.g., PH002, CB-5083 derivatives) bind the APOE4 N-terminal domain, stabilizing a structure resembling APOE3 and reducing toxicity.

Target Gene/Protein/Pathway: APOE4 protein structure;

Critical Evaluation of APOE4 Targeting Hypotheses

Overview

The presented hypotheses represent a coherent therapeutic portfolio targeting APOE4 through distinct mechanisms. However, several cross-cutting concerns apply across multiple hypotheses:

General Weaknesses:

• Most evidence derives from mouse models that imperfectly recapitulate human AD pathology
• APOE4's mechanistic role in human AD remains partially unresolved (lipid transport vs. direct toxicity)
• The relative contribution of neuronal vs. astrocytic vs. microglial APOE4 to neurodegeneration is unclear
• Human translati

Feasibility Assessment: APOE4 Targeting Hypotheses

Preliminary Filtering

Before detailed analysis, three hypotheses should be substantially deprioritized based on fundamental flaws:

| Hypothesis | Primary Disqualifier |
|------------|----------------------|
| H4: LXR Agonism | LXR activation increases APOE expression via LXR response elements—the proposed mechanism is self-contradicting. This isn't a minor gap; it invalidates the entire therapeutic premise. GW3965's amyloid benefits in APP/PS1 mice largely operate through APOE-independent pathways. |
| **H6: Passive Immuniza

{
"ranked_hypotheses": [
{
"title": "AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype",
"description": "Deliver AAV vectors encoding human APOE3 or APOE2 under astrocyte-specific promoters (GFAP, GFA2) to produce protective isoforms in APOE4/4 patients, creating a mosaic where corrected astrocytes secrete protective APOE that competes with endogenous APOE4. Already entered Phase I trials showing initial safety, though primate CNS penetration remains a critical translational barrier.",
"target_gene": "APOE",
"dimension_scores": {
"evidence_st